Regenxbio Inc
RGNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$500.95M
Close$
$25.02
151.2% upside
Current Fair Value
151.2% upsideUndervalued by 151.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $500.95 Million |
|---|---|
| Enterprise Value | $562.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.76 |
| Beta | 0.9 |
| Outstanding Shares | 52,428,000 |
Return
| Return on Equity | -1375.64% |
|---|---|
| Return on Assets | -84.83% |
| Return on Invested Capital | -93.54% |
Valuation & Multiples
| P/E Ratio | -1.73 |
|---|---|
| PEG | 0.11 |
| Price to Sales | 9.96 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.41 |
| Enterprise Value to EBIT | -2.22 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 3.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.36
Average shareholder expectationRevenue Estimate
$25.84 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.29
Average shareholder expectationRevenue Estimate
$111.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 67.78% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.03%▼ 81.55% |
|---|---|
| Total Invested | $6.57M▼ 98.15% |
| Investors Holding | 27▼ 162.00% |
ESG Score
No data
About Regenxbio Inc
CEO: Kenneth Mills